What was the result of the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-A) trial?
The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-A) trial compared aspirin plus clopidogrel vs aspirin monotherapy among patients in whom VKA was. The study found a decrease in risk of stroke with dual antiplatelet therapy (DAPT), but the major bleeding rates with aspirin-clopidogrel were comparable to rates seen with warfarin (approximately 2% per year).